What is the average price target for SEAGEN INC (SGEN) stock?
23 analysts have analysed SGEN and the average price target is 233.48 USD. This implies a price increase of 2.07% is expected in the next year compared to the current price of 228.74.
NASDAQ:SGEN • US81181C1045
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SEAGEN INC (SGEN).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-10-18 | Truist Securities | Reiterate | Hold -> Hold |
| 2023-09-25 | Truist Securities | Reiterate | Hold -> Hold |
| 2023-08-03 | Morgan Stanley | Reiterate | Equal-Weight -> Equal-Weight |
| 2023-03-24 | Berenberg | Downgrade | Buy -> Hold |
| 2023-03-21 | TD Securities | Maintains | Market Perform |
| 2023-03-20 | Truist Securities | Maintains | Hold |
| 2023-03-15 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2023-03-14 | BMO Capital | Downgrade | Outperform -> Market Perform |
| 2023-03-14 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2023-03-14 | Needham | Downgrade | Buy -> Hold |
| 2023-03-14 | Oppenheimer | Maintains | Outperform |
| 2023-03-14 | RBC Capital | Maintains | Outperform |
| 2023-03-14 | Barclays | Maintains | Equal-Weight |
| 2023-03-14 | Raymond James | Downgrade | Strong Buy -> Market Perform |
| 2023-03-13 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2023-03-06 | Needham | Maintains | Buy |
| 2023-02-28 | Guggenheim | Reiterate | Buy |
| 2023-02-28 | Oppenheimer | Maintains | Outperform |
| 2023-02-23 | Needham | Maintains | Buy |
| 2023-02-21 | Oppenheimer | Maintains | Outperform |
| 2023-02-17 | JMP Securities | Maintains | Market Outperform |
| 2023-02-17 | Oppenheimer | Maintains | Outperform |
| 2023-02-16 | BMO Capital | Maintains | Outperform |
| 2023-02-16 | Needham | Reiterate | Buy |
| 2023-02-16 | RBC Capital | Maintains | Outperform |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.176B 137.32% | 1.574B -27.63% | 1.962B 24.64% | 2.505B 27.65% | 3.318B 32.46% | 4.277B 28.90% | 5.329B 24.60% | 6.318B 18.56% | 7.178B 13.61% | 8.267B 15.17% | 8.993B 8.78% | |
| EBITDA YoY % growth | 649.2M 430.05% | -616.1M -194.90% | -543.2M 11.83% | -776.198M -42.89% | -345.024M 55.55% | 259.11M 175.10% | 774.31M 198.83% | 1.337B 72.67% | 1.748B 30.74% | 2.088B 19.45% | 2.448B 17.24% | |
| EBIT YoY % growth | 596.9M 370.70% | -682.1M -214.27% | -613M 10.13% | -838.377M -36.77% | -426.666M 49.11% | 115.42M 127.05% | 784.71M 579.87% | 1.451B 84.91% | 2B 37.84% | 2.594B 29.70% | 3.055B 17.77% | |
| Operating Margin | 27.44% | -43.32% | -31.24% | -33.47% | -12.86% | 2.70% | 14.73% | 22.97% | 27.86% | 31.38% | 33.97% | |
| EPS YoY % growth | 3.30 436.73% | -3.70 -212.12% | -3.30 10.81% | -4.25 -28.74% | -2.01 52.66% | 0.62 130.94% | 3.77 505.62% | 6.78 79.96% | 8.95 31.96% | 11.75 31.31% | 13.29 13.11% |
All data in USD
| Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.98 -22.67% | -0.75 19.28% | -0.64 43.31% | -0.59 48.91% | -0.69 30.10% |
| Revenue Q2Q % growth | 698.3M 32.20% | 715.71M 37.72% | 783.41M 29.75% | 838.64M 29.28% | 891.65M 27.69% |
| EBITDA Q2Q % growth | -199.242M -136.63% | -88.709M 34.96% | -85.445M 51.83% | -96.869M 43.97% | -100.031M 49.79% |
| EBIT Q2Q % growth | -184.668M -19.91% | -132.275M 14.39% | -111.362M 47.89% | -104.376M 54.28% | -132.772M 28.10% |
All data in USD
23 analysts have analysed SGEN and the average price target is 233.48 USD. This implies a price increase of 2.07% is expected in the next year compared to the current price of 228.74.
SEAGEN INC (SGEN) will report earnings on 2024-02-13, after the market close.
The consensus EPS estimate for the next earnings of SEAGEN INC (SGEN) is -0.98 USD and the consensus revenue estimate is 698.30M USD.
The consensus rating for SEAGEN INC (SGEN) is 72.1739 / 100 . This indicates that analysts generally have a positive outlook on the stock.